Market News AIOpen the app

Humacyte has sent a new application to the FDA for its vessel to be used in dialysis access.

TrialRead the original at globenewswire.com
Good for HUMA

Humacyte's application is backed by 3 Phase 3 trials, including a result showing women reached functional access faster. FDA approval is still pending, but the filing creates a promising path to another use.

HUMA · Humacyte, Inc.

AI read · Good for HUMA

The AI's read

That filing gives ATEV a chance to gain a second approved use, beyond its existing approval for extremity vascular trauma. Three Phase 3 trials support the application, and one found women reached functional access faster than with traditional options. The FDA has not approved this use, so sales from dialysis access are not yet established.

Get alerts for HUMA

Follow Humacyte, Inc. (HUMA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for HUMA
Free on the App Store and Google Play, or on the web.